Pacira BioSciencesPCRX +1.91%74 Net Margin % is 1.64% as of Mar. 2026, which is 290% above its 10-year median of 0.42. GuruFocus rates PCRX with a GF Score™ of 74/100 and a GF Value™ of $29.50 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Pacira BioSciences ranks worse than 64.54% on this metric.
The historical rank and industry rank for Pacira BioSciences's Net Margin % or its related term are showing as below:
PCRX'
s Net Margin % Range Over the Past 10 Years
Min: -14.87 Med: 0.42 Max: 33.87
Current: 0.7
PCRX's Net Margin % is ranked worse than 64.54% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs PCRX: 0.70
Pacira BioSciences (NAS:PCRX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Pacira BioSciences Net Margin % Related Terms
Pacira BioSciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (PCRX) has a Net Margin % of 1.64% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Pacira BioSciences and its competitors. This is 290% above median its historical median of 0.42. According to the industry distribution chart, Pacira BioSciences ranks #617 out of 956 companies in the Drug Manufacturers industry, placing it in the top 64.5%.
Is Pacira BioSciences' Net Margin % too high?
Pacira BioSciences' current Net Margin % of 1.64% is 290% above median its 10-year median of 0.42. The Drug Manufacturers industry median Net Margin % is 5.56. Pacira BioSciences' value of 1.64% is 70.5% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #617 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pacira BioSciences has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Net Margin % compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #617 out of 956 companies for Net Margin %. This places Pacira BioSciences in the lower half of its industry. The industry median Net Margin % is 5.56. Pacira BioSciences' value of 1.64% is 70.5% below this benchmark. While the company's 10-year median is 0.42 vs. the industry median of 5.56, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Net Margin % of 1.64% is 70.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Net Margin % is 1.64%, which is 290% above median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.50, compared to a current price of $23.98 — trading 18.7% below its estimated fair value. The current Net Margin % is 1.64%, which is 290% above median its 10-year median of 0.42 and 70.5% below the Drug Manufacturers industry median of 5.56. Pacira BioSciences' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current Net Margin % is 1.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (PCRX) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of $23.98 is trading 18.7% below its estimated GF Value™ of $29.50.
GuruFocus considers Pacira BioSciences to be Modestly Undervalued.
Key valuation signals for PCRX:
Net Margin %: 1.64% (290% above median its 10-year median of 0.42)
GF Value™: $29.50 vs. price of $23.98 (18.7% below fair value)
Industry Position: 70.5% below the Drug Manufacturers median (#617 of 956)
No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
74GF Score
Get the complete analysis for PCRX
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCRX has been successfully added to your 
